700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Original Articles Open Access
The purpose of the present study was to formulate t he oral controlled release Trimtazidine di hydrochloride tablets by using Polysaccharide B-145 9 (14-38%) as rate controlling polymer. The tablets were prepared by direct compression met hod and coated by the film coating polymers. The powder mixtures were evaluated for an gle of repose, loose bulk density, tapped bulk density and compressibility index, shows satis factory results. All the ingredients were lubricated and compressed using 8mm circular shaped deep concave punches. Compressed tablets were evaluated for uniformity of weight, co ntent of active ingredient, thickness, friability, hardness and In-vitro dissolution studies. Drug con tent in formulation was determined by HPLC Method . All the formulation showed compliance with Pharmacopoeial standards. The in vitro release study of matrix tablets were carried out in 0.1N Hydrochloric acid with pH 1.2 for 10 hours . The prepared matrix tablets were shown 98.00%, 99.0 0%, 100.00%, 104.00%, 92.00% and 100.00% release over a period of 10 hours. Form ulation F1, F2 and F3 failed to sustain release beyond 10 hours. Among all the formulation, F6 shows 100.00% release at the end of 10 hours. It was observed that the amount of polymer influences the drug release. In vitro release study results revealed that the release of drug was retarded with the proportional increase of the polymer concentration. It was indicated that the us ing a hydrophilic non-cellulosic polymer in an appropriate combination in tablet could control the rate of drug release.
To read the full article Peer-reviewed Article PDF
Author(s): Raj KumarMarikanti Kiran JoshiPVidya SagarCH Venkateswara reddyBKiran kumarANagarajuISrinivasa RaoPandJRavi kiran
Trimtazidine dihydrochloride, Matrix tablets, direct compression, Controlled release., Trimtazidine Dihydrochloride